DE69829202D1 - Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen - Google Patents

Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Info

Publication number
DE69829202D1
DE69829202D1 DE69829202T DE69829202T DE69829202D1 DE 69829202 D1 DE69829202 D1 DE 69829202D1 DE 69829202 T DE69829202 T DE 69829202T DE 69829202 T DE69829202 T DE 69829202T DE 69829202 D1 DE69829202 D1 DE 69829202D1
Authority
DE
Germany
Prior art keywords
mirtazapine
apnoes
sleep
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69829202T
Other languages
English (en)
Other versions
DE69829202T2 (de
Inventor
Stuart Andrews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69829202D1 publication Critical patent/DE69829202D1/de
Publication of DE69829202T2 publication Critical patent/DE69829202T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69829202T 1997-11-14 1998-11-13 Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen Expired - Fee Related DE69829202T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97203548 1997-11-14
EP97203548 1997-11-14
PCT/EP1998/007330 WO1999025356A1 (en) 1997-11-14 1998-11-13 Use of mirtazapine for treating sleep apneas

Publications (2)

Publication Number Publication Date
DE69829202D1 true DE69829202D1 (de) 2005-04-07
DE69829202T2 DE69829202T2 (de) 2005-07-21

Family

ID=8228923

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69829202T Expired - Fee Related DE69829202T2 (de) 1997-11-14 1998-11-13 Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Country Status (21)

Country Link
US (1) US6303595B1 (de)
EP (1) EP1030667B1 (de)
JP (1) JP2001522891A (de)
KR (1) KR20010032009A (de)
CN (1) CN1154495C (de)
AT (1) ATE289816T1 (de)
AU (1) AU737590B2 (de)
BR (1) BR9815098A (de)
CA (1) CA2309744A1 (de)
CZ (1) CZ296282B6 (de)
DE (1) DE69829202T2 (de)
DK (1) DK1030667T3 (de)
ES (1) ES2238781T3 (de)
HK (1) HK1029932A1 (de)
HU (1) HUP0100080A3 (de)
IL (2) IL135825A0 (de)
NO (1) NO20002218L (de)
PL (1) PL192272B1 (de)
PT (1) PT1030667E (de)
TR (1) TR200001293T2 (de)
WO (1) WO1999025356A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1066036T3 (da) 1998-02-27 2006-08-21 Univ Illinois Midler med serotoninrelateret aktivitet til behandling af sövnapnö
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
CZ302368B6 (cs) * 2000-02-11 2011-04-13 N.V. Organon Farmaceutický prostredek
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
MX2009010967A (es) 2007-04-11 2009-12-15 Organon Nv Un metodo para la preparacion de mirtazapina.
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
WO2013188806A1 (en) * 2012-06-14 2013-12-19 The Regents Of The University Of Michigan Sleep apnea treatment
EP3261645B1 (de) 2015-02-27 2021-04-28 Dechra Limited Anregung des appetits, verwaltung von gewichtsverlust und behandlung von anorexie bei hunden und katzen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
EP0517984A1 (de) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Amidanaloge-Derivate von methanoverbrückten Chinolizinen
ATE333880T1 (de) * 1995-10-24 2006-08-15 Gruenenthal Gmbh Montirelin zur verhinderung der schlafapnoe
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent

Also Published As

Publication number Publication date
CN1154495C (zh) 2004-06-23
EP1030667A1 (de) 2000-08-30
PT1030667E (pt) 2005-06-30
CA2309744A1 (en) 1999-05-27
CZ296282B6 (cs) 2006-02-15
IL135825A0 (en) 2001-05-20
CN1278731A (zh) 2001-01-03
ATE289816T1 (de) 2005-03-15
HUP0100080A3 (en) 2002-05-28
PL340467A1 (en) 2001-02-12
HUP0100080A2 (hu) 2001-08-28
BR9815098A (pt) 2000-10-10
AU737590B2 (en) 2001-08-23
AU1754899A (en) 1999-06-07
CZ20001751A3 (cs) 2000-10-11
NO20002218L (no) 2000-05-12
KR20010032009A (ko) 2001-04-16
DK1030667T3 (da) 2005-06-20
ES2238781T3 (es) 2005-09-01
PL192272B1 (pl) 2006-09-29
NO20002218D0 (no) 2000-04-28
US6303595B1 (en) 2001-10-16
TR200001293T2 (tr) 2002-09-23
DE69829202T2 (de) 2005-07-21
JP2001522891A (ja) 2001-11-20
EP1030667B1 (de) 2005-03-02
HK1029932A1 (en) 2001-04-20
WO1999025356A1 (en) 1999-05-27
IL135825A (en) 2006-12-31

Similar Documents

Publication Publication Date Title
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
EE200200337A (et) Uued ühendid ning nende kasutamine
DE69227583T2 (de) Arylmorpholine, herstellung und verwendung
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
SE0004101D0 (sv) New use
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE369856T1 (de) Verfahren zur behandlung von glaukom
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
NZ335057A (en) Pentaerythritol derivatives, their production and use and intermediates for their synthesis
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DE69516602D1 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
ATE367824T1 (de) Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

8339 Ceased/non-payment of the annual fee